Cartalax 10mg (10 vials/kit): Cartilage Bioregulator Tripeptide for Articular & Chondrocyte Research

Cartalax is a synthetic bioregulatory tripeptide with the chemical sequence $\text{H-Ala-Glu-Asp-OH}$ ($\text{L-Alanyl-L-Glutamyl-L-Aspartic Acid}$). Belonging to the short-chain peptide class (Khavinson peptide family), Cartalax was rationally designed to selectively regulate metabolic function and gene expression in primary chondrocytes and articular cartilage tissue. Sourcing Cartalax 10mg (10 vials/kit) provides orthopaedic researchers, rheumatological laboratories, and tissue engineering facilities with a high-purity analytical reagent engineered to investigate extracellular matrix ($\text{ECM}$) restoration, proteoglycan synthesis, and osteoarthritic cartilage degeneration cascades in vitro.

In cartilage physiology and cell culture models, short-chain bioregulatory tripeptides like Cartalax penetrate cell membranes and nuclear envelopes to interact directly with nucleosome histones and DNA strands. This interaction induces chromatin structural changes that upregulate the transcription of key structural proteins—specifically collagen type II and aggrecan—in primary chondrocytes. Simultaneously, Cartalax suppresses catabolic enzymatic pathways, downregulating matrix metalloproteinases ($\text{MMP-1}$, $\text{MMP-13}$) and inflammatory cytokines ($\text{IL-1}\beta$, $\text{TNF-}\alpha$) that drive proteoglycan depletion in joint tissue:

Maintaining batch uniformity and chemical stability is critical for quantitative receptor kinetics, gene expression assays, and cartilage tissue explant studies. The Cartalax 10mg (10 vials/kit) configuration supplies a total yield of 100mg active peptide material (10mg per vial) distributed across ten individual USP Type I borosilicate glass vials. Freeze-dried under sterile vacuum conditions, each vial contains a uniform, highly stable lyophilized powder cake. This multi-vial kit format enables research personnel to reconstitute only the working volume needed for immediate experimental runs, keeping remaining kit stock preserved in deep-freeze stasis to protect against thermal degradation and hydrolytic cleavage.

Chondrocyte Bioregulation, ECM Dynamics, and Technical Profile

The primary scientific value of Cartalax 10mg (10 vials/kit) stems from its epigenetic gene regulation, chondrocyte normalization, and cartilage matrix protective mechanisms:

• Epigenetic Transcriptional Activation: Interacts directly with DNA-histone complexes in chondrocyte nuclei to restore protein synthesis inhibited by cellular aging or inflammatory stress.

• Collagen Type II & Aggrecan Upregulation: Stimulates primary chondrocytes to increase production of essential extracellular matrix proteins, preserving cartilage structural integrity.

• Suppression of Matrix Metalloproteinases: Downregulates expression of catabolic enzymes such as $\text{MMP-3}$ and $\text{MMP-13}$, preventing enzymatic cleavage of collagen fibrils and proteoglycans.

• Chondrocyte Cytoprotection: Reduces apoptosis in human articular chondrocytes exposed to oxidative stress or inflammatory signaling in co-culture models.

• Ultra-High Chemical Purity ($\ge$99.0%): Synthesized via automated Solid-Phase Peptide Synthesis ($\text{SPPS}$) and purified using preparative High-Performance Liquid Chromatography ($\text{HPLC}$) to ensure complete removal of deletion sequences and synthesis byproducts.

Reconstitution Guidelines, Laboratory Storage Standards, and Quality Protocols

Achieving reproducible, publication-grade results when working with Cartalax 10mg (10 vials/kit) requires strict adherence to standardized laboratory preparation and climate-controlled storage protocols.

Perform all reconstitution procedures inside a certified Class II Biosafety Cabinet:

1. Temperature Balancing: Allow the frozen Cartalax vial to adjust to ambient room temperature prior to solvent introduction to eliminate moisture condensation inside the glass container.

2. Septum Sanitization: Remove the protective plastic flip-cap and thoroughly wipe the synthetic rubber stopper with a fresh 70% isopropyl alcohol pad. Allow the surface to dry completely.

3. Slow Diluent Addition: Using a sterile syringe equipped with a fine-gauge needle, draw the required volume of Bacteriostatic Water (0.9% benzyl alcohol), Sterile Normal Saline (0.9% NaCl), or Phosphate-Buffered Saline (PBS). Direct the liquid stream against the inner glass wall so it trickles slowly over the lyophilized cake.

4. Gentle Hydration: Allow the diluent to fully hydrate the powder cake for 2 minutes. Gently roll the vial between your palms or swirl in smooth circular motions until clear. Never vortex or shake vigorously, as high-shear agitation can disrupt peptide bonds and induce protein foaming.

5. Micro-Aliquot Strategy: For multi-week testing protocols, divide reconstituted liquid into sterile, single-use microcentrifuge tubes under aseptic conditions to prevent atmospheric oxidation and eliminate repeated freeze-thaw cycles.

Batch Quality Documentation & Traceability: Every production lot of Cartalax 10mg (10 vials/kit) undergoes third-party analytical testing. High-Performance Liquid Chromatography (HPLC) chromatograms confirm component purity exceeding 99.0%, while Electrospray Ionization Mass Spectrometry (ESI-MS) confirms precise theoretical molecular mass. Each shipment includes a batch-specific Certificate of Analysis (COA) documenting chemical purity, residual solvent analysis, heavy metal screens, and bacterial endotoxin levels (<0.05 EU/mg) to satisfy institutional compliance requirements.

Strict Regulatory & Research Compliance Statement: Cartalax 10mg (10 vials/kit) is produced, packaged, and distributed exclusively for in vitro laboratory research, academic experimentation, chemical synthesis, and preclinical research. Cartalax 10mg (10 vials/kit) is strictly not intended, formulated, or approved for human or animal consumption, therapeutic medical treatment, clinical diagnostic work, or cosmetic applications. All handling must be conducted by certified research personnel operating within equipped laboratory facilities in compliance with OSHA workplace safety regulations and institutional biosafety protocols.